Ciliary Neurotrophic FactorAx15 Alters Energy Homeostasis, Decreases Body Weight, and Improves Metabolic Control in Diet-Induced Obese and UCP1-DTA Mice

  1. Susann Blüher1,
  2. Stergios Moschos1,
  3. John Bullen, Jr.1,
  4. Efi Kokkotou2,
  5. Eleftheria Maratos-Flier2,
  6. Stanley J. Wiegand3,
  7. Mark W. Sleeman3 and
  8. Christos S. Mantzoros1
  1. 1Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  2. 2Joslin Diabetes Center, Harvard Medical School, Research Division, Boston, Massachusetts
  3. 3Regeneron Pharmaceuticals, Tarrytown, New York
  1. Address correspondence and reprint requests to Susann Blüher, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Ave., Boston, MA 02215. E-mail: sblueher{at}caregroup.harvard.edu

Abstract

Ciliary neurotrophic factor (CNTF) potently reduces appetite and body weight in rodents and humans. We studied the short- and long-term effects of CNTFAx15, a second-generation CNTF analog, in diet-induced obese C57BL/6J mice and brown adipose tissue (BAT)-deficient obese UCP1-DTA (uncoupling protein 1–diphtheria toxin A) mice. CNTFAx15 administration (0.1, 0.3, or 1.0 μg · g−1 · day−1 s.c.) for 3 or 7 days reduced food intake and body weight (mainly body fat mass). The effect of CNTFAx15 on food intake and body weight was more pronounced in CNTFAx15-treated diet-induced obese C57BL/6J mice compared with pair-fed controls and was associated with suppressed expression of hypothalamic neuropeptide Y and agouti gene–related protein. Moreover, CNTFAx15 increased uncoupling protein 1 mRNA expression in BAT and energy expenditure in diet-induced obese C57BL/6J mice. Longitudinal observations revealed a sustained reduction in body weight for several days post-CNTFAx15 treatment of CNTFAx15-treated but not pair-fed mice, followed by a gradual regain in body weight over 28 days. Finally, CNTFAx15 administration improved the metabolic profile in both diet-induced obese C57BL/6J and UCP1-DTA mice and resulted in a significantly improved glycemic response to oral glucose tolerance tests in CNTFAx15-treated UCP1-DTA compared with pair-fed mice of similar body weight. These data suggest that CNTFAx15 may act through a pathway downstream of the putative point responsible for leptin resistance in diet-induced obese C57BL/6J and UCP1-DTA mice to alter food intake, body weight, body composition, and metabolism. CNTFAx15 has delayed and persistent effects in diet-induced obese C57BL/6J mice, which account for a reduction in body weight over and above what would be expected based on decreased foot intake alone.

Footnotes

« Previous | Next Article »Table of Contents